Form 8-K - Current report:
SEC Accession No. 0001104659-23-041237
Filing Date
2023-04-04
Accepted
2023-04-04 08:39:28
Documents
12
Period of Report
2023-04-04
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2311180d3_8k.htm   iXBRL 8-K 28896
  Complete submission text file 0001104659-23-041237.txt   204735

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230404.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230404_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230404_pre.xml EX-101.PRE 22599
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2311180d3_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 23795198
SIC: 2834 Pharmaceutical Preparations